News & Updates

Repeat transarterial chemoembolization (TACE) is not recommended for patients with hepatocellular carcinoma (HCC) who have persistent liver function deterioration after initial TACE, particularly if they have suboptimal baseline liver function or excessive tumour burden, according to researchers from the Chinese University of Hong Kong (CUHK).

De-escalation of chemotherapy dose and trastuzumab duration may not increase the risk of distant relapse or death in patients with ERBB2-positive (also referred to as HER2-positive) early breast cancer and tumour infiltrating lymphocyte (TIL) levels of ≥20 percent, according to a 10-year analysis of the phase III ShortHER trial.